vs
Side-by-side financial comparison of Expensify, Inc. (EXFY) and LIFECORE BIOMEDICAL, INC. \DE\ (LFCR). Click either name above to swap in a different company.
Expensify, Inc. is the larger business by last-quarter revenue ($35.2M vs $31.1M, roughly 1.1× LIFECORE BIOMEDICAL, INC. \DE\). On growth, LIFECORE BIOMEDICAL, INC. \DE\ posted the faster year-over-year revenue change (-4.5% vs -4.9%). Over the past eight quarters, Expensify, Inc.'s revenue compounded faster (2.4% CAGR vs -0.1%).
Expensify, Inc. is a software company that develops an expense management system for personal and business use. Expensify also offers a business credit card called the Expensify Card.
LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.
EXFY vs LFCR — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $35.2M | $31.1M |
| Net Profit | — | $-10.0M |
| Gross Margin | 49.2% | 25.0% |
| Operating Margin | -11.2% | -9.9% |
| Net Margin | — | -32.1% |
| Revenue YoY | -4.9% | -4.5% |
| Net Profit YoY | — | -52.0% |
| EPS (diluted) | $-0.07 | $-0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $35.2M | — | ||
| Q3 25 | $35.1M | $31.1M | ||
| Q2 25 | $35.8M | — | ||
| Q1 25 | $36.1M | $35.2M | ||
| Q4 24 | $37.0M | $32.6M | ||
| Q3 24 | $35.4M | $24.7M | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $33.5M | $35.7M |
| Q4 25 | — | — | ||
| Q3 25 | $-2.3M | $-10.0M | ||
| Q2 25 | $-8.8M | — | ||
| Q1 25 | $-3.2M | $-14.8M | ||
| Q4 24 | — | $-6.6M | ||
| Q3 24 | $-2.2M | $-16.2M | ||
| Q2 24 | $-2.8M | — | ||
| Q1 24 | $-3.8M | $15.6M |
| Q4 25 | 49.2% | — | ||
| Q3 25 | 49.6% | 25.0% | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 50.6% | 28.0% | ||
| Q4 24 | 51.0% | 34.0% | ||
| Q3 24 | 51.6% | 21.8% | ||
| Q2 24 | 56.9% | — | ||
| Q1 24 | 56.5% | 33.3% |
| Q4 25 | -11.2% | — | ||
| Q3 25 | -6.4% | -9.9% | ||
| Q2 25 | -28.9% | — | ||
| Q1 25 | -4.1% | -25.7% | ||
| Q4 24 | 1.3% | -6.0% | ||
| Q3 24 | 0.8% | -46.9% | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | -5.3% | -2.5% |
| Q4 25 | — | — | ||
| Q3 25 | -6.6% | -32.1% | ||
| Q2 25 | -24.6% | — | ||
| Q1 25 | -8.8% | -42.0% | ||
| Q4 24 | — | -20.2% | ||
| Q3 24 | -6.2% | -65.7% | ||
| Q2 24 | -8.3% | — | ||
| Q1 24 | -11.3% | 43.8% |
| Q4 25 | $-0.07 | — | ||
| Q3 25 | $-0.03 | $-0.29 | ||
| Q2 25 | $-0.10 | — | ||
| Q1 25 | $-0.03 | $-0.47 | ||
| Q4 24 | $-0.03 | $-0.25 | ||
| Q3 24 | $-0.02 | $-0.53 | ||
| Q2 24 | $-0.03 | — | ||
| Q1 24 | $-0.04 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.1M | $18.9M |
| Total DebtLower is stronger | — | $136.0M |
| Stockholders' EquityBook value | $132.7M | $-10.5M |
| Total Assets | $186.0M | $235.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.1M | — | ||
| Q3 25 | $61.5M | $18.9M | ||
| Q2 25 | $60.5M | — | ||
| Q1 25 | $59.6M | $5.4M | ||
| Q4 24 | $48.8M | $9.5M | ||
| Q3 24 | $39.2M | — | ||
| Q2 24 | $53.2M | — | ||
| Q1 24 | $49.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $136.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $124.9M | ||
| Q4 24 | — | $111.3M | ||
| Q3 24 | — | $106.3M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $97.1M |
| Q4 25 | $132.7M | — | ||
| Q3 25 | $135.7M | $-10.5M | ||
| Q2 25 | $131.8M | — | ||
| Q1 25 | $134.7M | $2.2M | ||
| Q4 24 | $128.2M | $15.4M | ||
| Q3 24 | $119.9M | $-3.9M | ||
| Q2 24 | $114.0M | — | ||
| Q1 24 | $106.5M | $17.7M |
| Q4 25 | $186.0M | — | ||
| Q3 25 | $186.8M | $235.2M | ||
| Q2 25 | $187.1M | — | ||
| Q1 25 | $189.2M | $237.7M | ||
| Q4 24 | $173.7M | $255.4M | ||
| Q3 24 | $176.2M | $246.8M | ||
| Q2 24 | $192.9M | — | ||
| Q1 24 | $184.8M | $246.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 56.05× | ||
| Q4 24 | — | 7.20× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 5.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.2M | $1.8M |
| Free Cash FlowOCF − Capex | — | $25.0K |
| FCF MarginFCF / Revenue | — | 0.1% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-16.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.2M | — | ||
| Q3 25 | $4.2M | $1.8M | ||
| Q2 25 | $8.9M | — | ||
| Q1 25 | $4.8M | $1.2M | ||
| Q4 24 | $7.4M | $-6.1M | ||
| Q3 24 | $3.7M | $-613.0K | ||
| Q2 24 | $9.3M | — | ||
| Q1 24 | $3.5M | $-1.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | $25.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-4.3M | ||
| Q4 24 | — | $-8.6M | ||
| Q3 24 | — | $-4.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-7.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -12.1% | ||
| Q4 24 | — | -26.3% | ||
| Q3 24 | — | -16.3% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -21.8% |
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | 5.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 15.5% | ||
| Q4 24 | 0.0% | 7.5% | ||
| Q3 24 | 0.0% | 13.9% | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | 17.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXFY
Segment breakdown not available.
LFCR
| Transferred At Point In Time | $26.6M | 85% |
| Transferred Over Time | $4.5M | 15% |
